Relationship between serum visfatin levels and coronary slow-flow phenomenon.
BACKGROUND
Increased levels of visfatin, a novel adipocytokine, are reported in atherosclerosis, obesity, and type 2 diabetes. The aim of the present study was to investigate the relationship between coronary slow flow (CSF) and visfatin in patients undergoing elective coronary angiography for suspected coronary artery disease.


METHODS
A total of 140 recruited participants (90 patients with CSF and 50 controls) were divided into two groups according to their coronary flow rates. Coronary flow was quantified by thrombolysis in myocardial infarction (TIMI) frame count (TFC).


RESULTS
Serum visfatin levels were higher in the CSF group than in the control group (3.29 ± 1.11 vs. 2.70 ± 1.08 ng/ml, p = 0.003). A significant correlation was found between TFC and visfatin (r = 0.535, p < 0.001). The area under the receiver operating characteristic curve was 0.720 (95 % confidence interval, 0.622-0.817, p < 0.001) for visfatin in the diagnosis of CSF. If a cut-off value of 2.59 ng/ml was used, higher levels of visfatin could predict the presence of CSF with 78.9 % sensitivity and 64.0 % specificity.


CONCLUSIONS
Visfatin levels might be a useful biomarker for predicting CSF in patients undergoing diagnostic coronary angiography.
Department of Cardiology, Rize Kackar Government Hospital, Rize, Turkey. altugcakmak@hotmail.com.
Huseyin Altug
HA
Cakmak
Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education and Training Hospital, Istanbul, Turkey.
Serkan
S
Aslan
Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education and Training Hospital, Istanbul, Turkey.
Ahmet Arif
AA
Yalcin
Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education and Training Hospital, Istanbul, Turkey.
Ibrahim Faruk
IF
Akturk
Department of Microbiology, Kanuni Sultan Suleyman Education and Training Hospital, Istanbul, Turkey.
Burce
B
Yalcin
Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education and Training Hospital, Istanbul, Turkey.
Fatih
F
Uzun
Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education and Training Hospital, Istanbul, Turkey.
Derya
D
Ozturk
Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education and Training Hospital, Istanbul, Turkey.
Mehmet
M
Erturk
Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education and Training Hospital, Istanbul, Turkey.
Mehmet
M
Gul
D060050:Angina, Stable / Q000097:blood* / Q000453:epidemiology*; D015415:Biomarkers / Q000097:blood; D023903:Coronary Restenosis / Q000097:blood / Q000453:epidemiology*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D054318:No-Reflow Phenomenon / Q000097:blood* / Q000453:epidemiology*; D015995:Prevalence; D011379:Prognosis; D015203:Reproducibility of Results; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D014421:Turkey / Q000453:epidemiology
D015415:Biomarkers; D054409:Nicotinamide Phosphoribosyltransferase
Biomarker; Coronary artery disease; Coronary slow flow; Thrombolysis in myocardial Infarction frame count; Visfatin